Basic Information
Amifampridine SERB
Regulatory Information
EMEA/H/C/005839
May 19, 2022
March 24, 2022
May 24, 2022
Company Information
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Overview Summary
Amifampridine Serb is a medicine used to treat the symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a disease in which patients have muscle weakness because of a failure of the nerves to transmit electrical impulses to the muscles. Amifampridine Serb contains the active substance amifampridine and is a ‘generic medicine’. This means that Amifampridine Serb contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Firdapse. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf).